This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 1 EPO patent. Top assignee: University of Wollongong. Active years: 2013.
Company Filing History:
Years Active: 2013
Title: Philip Clingan: Innovator in Anti-Cancer Delivery Systems
Introduction
Philip Clingan is a notable inventor based in Barrack Point, Australia. He has made significant contributions to the field of cancer treatment through his innovative research and development of pharmaceutical compositions. His work focuses on enhancing the delivery of anti-cancer agents, which is crucial for improving patient outcomes.
Latest Patents
Philip Clingan holds a patent for "Compositions and methods for delivery of anti-cancer agents." This invention relates to compositions that include 5-fluorouracil, or a pharmaceutically acceptable salt or analogue thereof, folinic acid, or a pharmaceutically acceptable salt thereof, and a cyclodextrin, or a pharmaceutically acceptable salt or derivative thereof. The invention also encompasses methods for treating cancer using these compositions. He has 1 patent to his name.
Career Highlights
Philip Clingan is affiliated with the University of Wollongong, where he contributes to research and development in the pharmaceutical sciences. His work is instrumental in advancing the understanding and application of anti-cancer therapies.
Collaborations
Some of his notable coworkers include John Barnard Bremner and Julie Myree Locke. Their collaborative efforts enhance the research environment and contribute to innovative solutions in cancer treatment.
Conclusion
Philip Clingan's work in developing compositions for the delivery of anti-cancer agents showcases his commitment to improving cancer therapies. His contributions are vital in the ongoing fight against cancer, and his innovative spirit continues to inspire advancements in the field.